Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer Sells 2,255 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 2,255 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares of the company’s stock, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Collegium Pharmaceutical Stock Up 0.5 %

COLL opened at $29.82 on Wednesday. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a 50-day moving average price of $30.89 and a 200 day moving average price of $32.81. The company has a market cap of $938.91 million, a PE ratio of 12.85 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Institutional Trading of Collegium Pharmaceutical

Hedge funds have recently bought and sold shares of the business. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $40,000. TD Private Client Wealth LLC raised its holdings in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the last quarter. KBC Group NV raised its holdings in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Virtus Fund Advisers LLC increased its holdings in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.